Tozadenant

N/A

Report date: 2022/08/08 13:36:57
NME

Base Information

Drug NameTozadenant
Drug Alias Nametozadenant托扎迪南tozadenantum托扎地南RO-449351 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsSubstance Abuse, OralCocaine-Related DisordersParkinson Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAcorda Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAcorda TherapeuticsVirginia Commonwealth UniversityUcb Sa +[4] 
Active IndicationsN/A
Inactive IndicationsSubstance Abuse, OralCocaine-Related DisordersParkinson Disease +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG